Edition:
India

Five Prime Therapeutics Inc (FPRX.OQ)

FPRX.OQ on NASDAQ Stock Exchange Global Select Market

6.12USD
2 Jul 2020
Change (% chg)

$-0.29 (-4.52%)
Prev Close
$6.41
Open
$6.56
Day's High
$6.56
Day's Low
$6.08
Volume
94,733
Avg. Vol
139,780
52-wk High
$7.21
52-wk Low
$1.76

Latest Key Developments (Source: Significant Developments)

Five Prime Therapeutics Q2 Loss Per Share $0.99
Thursday, 8 Aug 2019 

Aug 7 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS REPORTS SECOND QUARTER 2019 RESULTS.Q2 LOSS PER SHARE $0.99.Q2 EARNINGS PER SHARE ESTIMATE $-0.90 -- REFINITIV IBES DATA.FIVE PRIME THERAPEUTICS - CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES TOTALED $214.1 MILLION AS OF JUNE 30, 2019, VERSUS $237.0 MILLION AS OF MARCH 31, 2019.EXPECTS FULL-YEAR 2019 NET CASH USED IN OPERATING ACTIVITIES TO BE BETWEEN $117 AND $122 MILLION.ESTIMATES ENDING 2019 WITH CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES BETWEEN $148 AND $153 MILLION..QTRLY COLLABORATION AND LICENSE REVENUE $3.3 MILLION VERSUS $7.6 MILLION.Q2 REVENUE VIEW $7.7 MILLION -- REFINITIV IBES DATA.  Full Article

Five Prime Therapeutics Reports Fourth Quarter Results
Wednesday, 27 Feb 2019 

Feb 26 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $1.12.Q4 EARNINGS PER SHARE ESTIMATE $-1.32 -- REFINITIV IBES DATA.COLLABORATION AND LICENSE REVENUE FOR Q4 OF 2018 DECREASED BY $9.2 MILLION TO $4.0 MILLION FROM $13.2 MILLION FOR Q4 OF 2017.EXPECTS FULL-YEAR 2019 NET CASH USED IN OPERATING ACTIVITIES TO BE BETWEEN $117 AND $122 MILLION.ESTIMATES ENDING 2019 WITH CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES BETWEEN $148 AND $153 MILLION.MULTIPLE DATA READOUTS IN 2019.  Full Article

Five Prime Therapeutics Estimates Its Cash, Cash Equivalents And Marketable Securities As Of Dec 31, 2018 Was About $270.1 Mln
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS - ESTIMATES ITS CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF DECEMBER 31, 2018 WAS ABOUT $270.1 MILLION.FIVE PRIME THERAPEUTICS - EXPECTS NET CASH USED IN OPERATING ACTIVITIES FOR FISCAL YEAR 2019 WILL BE BETWEEN $117 MILLION AND $122 MILLION.FIVE PRIME THERAPEUTICS - EXPECTS CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES AS OF DEC 31, 2019 WILL BE BETWEEN $148 MILLION AND $153 MILLION - SEC FILING.  Full Article

Five Prime Therapeutics Announces Changes To Its Board Of Directors
Friday, 30 Nov 2018 

Nov 29 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS.FIVE PRIME THERAPEUTICS INC - WILLIAM RINGO WILL BECOME CHAIRMAN OF BOARD EFFECTIVE JANUARY 1, 2019.FIVE PRIME THERAPEUTICS INC - LEWIS T. WILLIAMS TO TRANSITION FROM EXECUTIVE CHAIRMAN TO BOARD MEMBER.  Full Article

Five Prime Therapeutics Q2 Loss Per Share $0.99
Thursday, 9 Aug 2018 

Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.99.Q2 EARNINGS PER SHARE VIEW $-1.29 -- THOMSON REUTERS I/B/E/S.ANTICIPATES INITIATING A PHASE 1 CLINICAL TRIAL OF FPT155 IN AUSTRALIA IN Q4 OF 2018.ESTIMATES ENDING 2018 WITH APPROXIMATELY $250 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES.COLLABORATION AND LICENSE REVENUE FOR Q2 OF 2018 DECREASED BY $0.2 MILLION, OR 3%, TO $7.6 MILLION.  Full Article